IGF1R and neoplasm: While in certain cancers, including Ewing’s and rhabdomyosarcoma, tumor IGF1R levels were correlated with responsiveness to IGF1R-directed therapies, most clinical data seem to indicate that IGF1R expression levels, per se, do not predict sensitivity to IGF1R inhibition (110).